Novo Nordisk: successful trial in type 2 diabetes
(CercleFinance.com) - Novo Nordisk has announced that a Phase 3b trial of once-daily oral semaglutide 25 mg and 50 mg in people with type 2 diabetes, requiring treatment intensification has met its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 compared to oral semaglutide 14 mg.
For example, from a mean baseline body weight of 96.4 kg, those treated with oral semaglutide 25 mg and 50 mg showed statistically significant weight loss of 7.0 kg and 9.2 kg, respectively, compared to a 4.5 kg reduction with oral semaglutide 14 mg.
Novo Nordisk plans to file for regulatory approval in the US and EU in 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
For example, from a mean baseline body weight of 96.4 kg, those treated with oral semaglutide 25 mg and 50 mg showed statistically significant weight loss of 7.0 kg and 9.2 kg, respectively, compared to a 4.5 kg reduction with oral semaglutide 14 mg.
Novo Nordisk plans to file for regulatory approval in the US and EU in 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.